Capital One analyst Zegbeh Jallah initiated coverage of Outlook Therapeutics with an Overweight rating and $5 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OTLK:
- Outlook Therapeutics participates in a conference call hosted by H.C. Wainwright
- Biotech Alert: Searches spiking for these stocks today
- OTLK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update